# tafamidis

Type: Product

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/tafamidis
Canonical HTML page: https://gethealthbrief.com/entity/tafamidis

## Recent coverage (1 stories)

### Vutrisiran benefit holds in 40% of ATTR-CM patients on tafamidis
2026-08-31 00:40:54 · Sentiment: Positive · Impact: 6/10 · Sources: 3

New ESC 2026 data suggest RNAi therapy vutrisiran provides consistent cardiovascular benefit in ATTR cardiomyopathy patients regardless of baseline tafamidis use, with implications for cardiology treatment pathways and broader hypertension management.
Full story: https://gethealthbrief.com/story/alnylam-esc-2026-vutrisiran-tafamidis-subgroup-health

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.